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Letters to the EditorGut immune reconstitution in immune dysre-
gulation, polyendocrinopathy, enteropathy,
X-linked syndrome after hematopoietic stem
cell transplantation
To the Editor:
Immune dysregulation, polyendocrinopathy, enteropathy,
X-linked syndrome (IPEX) is an inherited syndrome of early-
onset systemic autoimmunity and the prototype of immune
dysregulatory disorders. It is caused by mutations of forkhead
box p3 (FOXP3) gene (Xp11.23), encoding a key transcription
factor for natural regulatory T (nTreg) cells.1 Treg cell dysfunc-
tion leads to severe multi-organ autoimmune phenomena
including enteropathy, dermatitis, endocrinopathy, and other
organ-specific diseases.2 Patients often present early in infancy
and, without treatment, usually die in the first years of life. The
only effective cure is hematopoietic stem cell transplantation
(HSCT). However, the outcome is variable. Early HSCT with
non-myeloablative conditioning provides the best outcome,
before organs are damaged by autoimmunity and/or adverse
effects of therapy.3 Complete donor engraftment in all hematopoi-
etic lineages may not be necessary, because the preferential
engraftment of donor Treg cells seems to be sufficient to control
the disease.4,5
With parental informed consent and Newcastle upon Tyne
Hospitals National Health Service Foundation Trust approval,
we report the case of an IPEX patient presenting with severe
enteropathy, dermatitis, and other signs of autoimmunity since 3
to 4 weeks of age. The identified FOXP3 gene mutation
was associated with a reduced protein expression in Treg cells
(Figs E1 and E2 available in this article’s Online Repository
at www.jacionline.org). Therefore, at 6 months of age, he
received an unmanipulated, unrelated donor cord blood stem
cell transplant (1 DP mismatch) with sub-myeloablative condi-
tioning and graft-versus-host disease (GvHD) prophylaxis (see
this article’s Methods section and Fig E3 in the Online
Repository at www.jacionline.org). He had an uneventful
engraftment and a reasonable immune reconstitution (Fig E4
in this article’s Online Repository at www.jacionline.org).
Chimerism analysis in peripheral blood showed 90% donor T
lymphocytes during the first 6 months after the transplant,
with a decrease and stabilization at 70% 1 year post-
transplant (Fig E5 in this article’s Online Repository at www.
jacionline.org). Consistent with the sub-myeloablative condi-
tioning regimen the patient has received, mixed myeloid chime-
rism was also observed; however, as previously reported,4-6
donor myeloid chimerism is not necessary to control the dis-
ease. Moreover, FOXP3 protein expression by Treg cells
increased over time (Fig E2).
Despite good post-transplant immune reconstitution, the
patient continued to suffer from diarrhea and malabsorption
and was dependent on parenteral nutrition. He developed
episodes of upper intestinal obstruction and, despite anti- 2014 The Authors. Published by Elsevier, Inc. on behalf of the Academy of Allergy,
Asthma& Immunology. This is an open access article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
260inflammatory therapy with an anti-TNF-a agent, required
jejunal resections at 3, 4, and 6 months. Histopathology of
resected areas revealed severe chronic mucosal injury without
histological signs of GvHD, with an improvement of the
architecture over time (see Fig E6 in this article’s Online
Repository at www.jacionline.org).7 The gut dysfunction
improved progressively from month 6 to 9, and at 1 year
post-transplant, the patient was independent of parenteral nutri-
tion and thriving on enteral feeding.
The intestine has a major interface with the external
environment, and its integrity is important in the maintenance
of immune homeostasis.8 The intestinal mucosa contains an
extensive network of secondary lymphoid tissues and is home
to several lymphocyte subsets, including intestine-specific
subpopulations. The beta-7 integrins (a4b7 and aEb7) are selec-
tive mediators of lymphocyte homing to the gut-associated
lymphoid tissue. In particular, a4b7 is expressed at low levels
on naive T and B cells and at high levels on effector and memory
T (mainly CD41) cells.9
Because the persistence of enteropathy in the patient was
inconsistent with the transplant outcome, we explored the
hypothesis that intestinal immune reconstitution proceeded at a
different pace to that in the peripheral blood with a delay in the
re-establishment of homeostasis within the gut immune system.
We therefore investigated the engraftment of donor lymphocytes
in the gut mucosa to evaluate any differences between peripheral
blood and gut immune reconstitution that might explain the
clinical course.
To study gut immune reconstitution, we probed for FOXP31
and CD41 T cells on tissue sections of small bowel mucosa at
different times after transplant (3, 6, and 9 months). We observed
the presence of lymphoid nodules numerically decreasing over
time, with an increased proportion of FOXP31 cells both within
nodules and the mucosal area (Fig 1), suggesting a reduction of
the small bowel inflammatory state.
We isolated CD41 cells from small bowel tissue sections
obtained at 3 months post-transplant and investigated their
origin by genotyping FOXP3 (donor or recipient) to evaluate
the donor chimerism within the relevant cellular compart-
ment. Both wild-type and mutated nucleotides were present
at the c.1037 position on the FOXP3 gene, suggesting a
mixed population of lymphocytes in the gut. This was
confirmed by chimerism analysis of polymorphic markers
on the same cell population showing 60% donor, 40% recip-
ient origin (Fig 2, A), while donor chimerism in the blood
CD31T cells was 91% (Fig E5). We set out to study circu-
lating gut-homing lymphocytes in a patient blood sample,
which was available at only 9 months after HSCT. We recov-
ered CD41CD311a4/b7low naive and CD41CD312a4/b7high
memory T cells by cell sorting. Sequence analysis showed
wild-type FOXP3 sequence and 90% donor chimerism on
CD41CD312a4b7high gut-homing lymphocytes, whereas
wild-type and mutated FOXP3 genes along with a 50%
donor chimerism were found on CD41CD311a4/b7low naive
T cells not specifically committed to the intestine (Fig 2, B
and C).
Our results suggest that, in this patient, the gut immune system
took longer to recover and function compared with the peripheral
FIG 1. FOXP3 ‘‘reactive nuclei’’ (arrow) in and around lymphoid follicles in small bowel mucosa and
submucosa on immunohistochemically stained sections at 3 months (A), 6 months (B), and 9 months
(C) post-transplant. (FOXP3 reactive nuclei are stained black, and the sections are counterstained with
hematoxylin.) D, Quantitative analysis of FOXP31nuclei in the examined total small bowel mucosal and
submucosal tissue.
FIG 2. Exon 9 FOXP3 sequencing and chimerism analysis on laser microdissected CD41 T cells from small
bowel biopsies at 3 months post-transplant (A) and on CD312CD41a4b7high memory T cells (B) and
CD311CD41a4b7low naive T cells (C) sorted from peripheral blood at 9 months post-transplant.
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bowel biopsies taken at different times post-transplant was found
to correlate with the patient’s clinical condition. Gut function and
tolerance of enteral nutrition progressively improved in parallel
with the increased FOXP3 expression within the gut mucosaand the appearance of donor CD41CD312a4/b7high cells.
Furthermore, cells of donor origin were mostly present in the
periphery rather than in the gut early after transplant,
possibly explaining poor gut function. The increase in donor
chimerism within gut-homing lymphocytes was associated with
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on, possibly suggesting that a preferential homing of donor
Treg cells to the gut is associated with disease recovery. Further
studies in additional patients will be required to determine if
this is applicable to other patients with IPEX.
To our knowledge, this is the first study of gut immune
reconstitution in a patient affected with an inherited disorder of
immune tolerance, and we believe it could be a unique case study
that sheds light on the role of the intestine in reconstituting the
immune system after HSCT. Further investigation of function of
external factors (such as microbiota) in influencing the imprinting
of mucosal immunity will help to identify new therapeutic
approaches.
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Upon Tyne, United Kingdom, for technical support in cell sorting.
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Recognizing mastocytosis in patients with
anaphylaxis: Value of KIT D816V mutation
analysis of peripheral blood
To the Editor:
Systemic mastocytosis (SM) is a disease with clonal
expansion of mast cells (MCs) that carries an increased risk
for anaphylaxis. SM is considered rare, but the disease is likely
to be underdiagnosed.1,2 The vast majority of adult patients
carry the somatic KIT D816V mutation. Sensitive mutation
analysis of peripheral blood (PB) has recently been demon-
strated as a promising diagnostic test in mastocytosis.3,4 In
extension of these results, we performed KIT D816V mutation
analysis of PB in 113 consecutive adult patients seen at Odense
University Hospital (OUH) with anaphylaxis from May 2013 to
January 2014.5 The study was approved by the local ethics
committee, and all patients provided written informed consent.
Patients were included in the study if they had been seen in the
emergency room of OUH with suspicion of anaphylaxis.
Patients with a known diagnosis of mastocytosis were not
excluded from the study; however, none of the 113 patients
had this at the time of inclusion. The KIT D816V mutation
was detected in 4 patients (3.5%). We present data on these 4
patients who were all subsequently diagnosed with indolent
SM. Three of the patients had bone marrow (BM) mastocytosis,
which is a subtype of indolent SM particularly difficult to
diagnose because of typically low s-tryptase level and absence
of skin lesions. The diagnosis was established by a full BM
investigation, including flow cytometry, and all the 4 patients
fulfilled the major as well as 3 minor World Health
Organization diagnostic criteria, thus demonstrating the clinical
utility of the test in this patient group.
Table I summarizes the acute anaphylactic episodes as well as
clinical, laboratory, and pathologic findings in the 4 patients.
They were all formerly healthy without any history of atopy or
anaphylaxis. All 4 experienced severe anaphylaxis with
hypotension and loss of consciousness, and were treated in the
acute phase according to guidelines for anaphylaxis.5,6 All
patients have been informed according to general recommenda-
tions for SM and equipped with an adrenaline autoinjector.
METHODS
Subject
The male child included in this study presented at 3 to 4 weeks of life with
severe enteropathy characterized by watery diarrhea that did not respond to
different types of enteral feeding. He then developed eczematous-like skin
changes. Moreover, he had been noted to be hypotonic at birth, with
dysmorphic facial characteristics. Small bowel biopsies evidenced an
eosinophilic infiltrate and villous atrophy.
Investigations showed a positive Coombs test, positive islet cell antibodies
and high IgE (1278 UI/L). The above-mentioned findings were suggestive for
IPEX syndrome. Genetic testing confirmed IPEX with a homozygous
missense mutation in exon 9 of FOXP3 (c.1037T>C), causing an amino
acid substitution (p.Iso346Thr) in the forkhead domain of the protein.E1 Anal-
ysis of FOXP3 protein on peripheral lymphocytes showed that its expression
was reduced and was lower in the patient’s Treg cells compared with those of
the normal control (37% of FOXP3 expressing CD41CD25bright cells in the
patient vs 82% in the control; Fig E2). Accordingly, immunohistochemistry
of small bowel biopsies revealed the presence of FOXP3 protein, although pre-
sumably it was not functional (Fig E1).
To cure his disease, at 6 months of age, the patient received an unmanip-
ulated, unrelated donor cord blood stem cell transplant (1 DP mismatch) with
sub-myeloablative conditioning (Alemtuzumab 0.3 mg/kg, Fludarabine 150
mg/m2, and Treosulfan 36 g/m2) and GvHD prophylaxis (tacrolimus, myco-
phenolate mofetil).E2
Written informed consent was obtained from the patient’s parents, and the
study was approved by the local ethics committee.
Immunologic studies
T, B, and natural killer cells were analyzed on peripheral blood at different
times after the transplant (Day 0 is considered the day of graft infusion).
Monoclonal antibodies specific for CD45RA, CD3, CD4, CD8, CD19, CD15,
CD16/56, and CD45 (BD Biosciences, San Jose, Calif) were used to define
percentage of cell subset on gated lymphocytes. Absolute numbers of CD81
cells, total CD41 and CD41 naive T cells, B cells, and natural killer cells
were calculated.
For identification of Treg cells, PBMCs were stained with the surface
molecules CD4 and CD25 and then fixed, permeabilized, and stained with
intracellular FOXP3 (eBioscience, San Diego, Calif). Cell fluorescence was
evaluated with FACSCanto II flow cytometry and analyzed with FACSDiva
software (BD, San Jose, Calif).
Immunohistochemistry and analysis of stained
sections
Immunohistochemistry to detect FOXP3 was carried out on tissue sections
received from the histopathology archives of Newcastle upon Tyne Teaching
Hospitals National Health Service Trust. All tissuewas used in accordancewith
Newcastle and North Tyneside Local Research Ethics Committee approval.
Immunohistochemistry methods were as previously published, with minor
modifications.E3 Fourmmparaffin sections onpositivelycharged slideswerede-
paraffinized and partially rehydrated to 95% ethanol. Endogenous peroxidase
wasblocked inmethanol/hydrogenperoxide for 10minutes at roomtemperature
(RT) followedbywashing in standardTRIS-buffered saline (TBS) (pH7.6).An-
tigen retrieval was achieved at low temperature (658C) in EDTA buffer (pH 8.0)
for approximately 21 hours in a hot air oven. Following a wash in TBS, endog-
enous biotin was blocked (Vector, Hartfield, United Kingdom), and nonspecific
bindingof antibodieswasminimizedby incubationof sectionswith 20%normal
swine serum (NSS) in TBS. Overnight incubation with primary antibody (anti-
FOXP3 at 1/10 in NSS) supernatant received from Dr Alison Banham, Oxford,
at 48C was followed by washing in TBS, then incubation at RT for 1 hour with
biotinylated goat anti-mouse immunoglobulins (Vector: 1/200 in NSS). Subse-
quently, the antibody complex was detected with avidin-biotin peroxidase
(Vector: 30 minutes at RT) and nickel diaminobenzidine substrate (Sigma-
Aldrich, St Louis, Mo) at RT. The counterstain was Mayer’s hematoxylin, and
slides were dehydrated, cleared, and mounted in distrene plasticizer xylene.
Sections were scanned using an Aperio ScanScope Digital Scanner (Leica
Biosystems, Nussloch, Germany). Analysis of digital images was carried out
with Imagescope software, and a nuclear algorithm was used to enumerate
black FOXP31 nuclei. Submucosal tissue was excluded from the analysis.
Preparation of membrane-mounted paraffin
sections for laser-assisted microdissection:
Identification of CD41 cell populations using
immunohistochemistry
Identification of CD41 cell populations for laser-assisted microdissection
was carried out according to Gjerdrum et al.E4 Serial 5 mm paraffin sections,
cut with a fresh blade, were placed on APES-coated PEN-membrane slides
and dried at 608C for 2 hours.
Deparaffinization was carried out in fresh xylene for at least 2 3 10
minutes, followed by prolonged washing and partial rehydration in absolute
then 95% ethanol. Subsequent steps to detect CD41 cells were as for FOXP31
cells above. Primary anti-CD4 antibody was used at 1/50 in NSS (Leica Bio-
systems, Novocastra).
No counterstain was applied, and slides were dehydrated in fresh ethanol
(graded) then stored at RT. Groups of CD41 T cells were subsequently micro-
dissected and collected by gravity into the lid of a 0.5-mL reaction tube using
Leica LMD6500 laser microdissector (Leica Microsystems) or isolated by
laser capture and pressure catapulting with the PALM Laser MicroBeam sys-
tem (Carl Zeiss MicroImaging GmbH, Oberkochen, Germany).
Gut-homing cell sorting
Gut-homing T cells were isolated with cell sorting (FACSAriaII, BD
Biosciences). Briefly, 500 uL of whole blood was stained with specific
monoclonal antibodies CD3-PerCp-Cy5.5, CD4-PE-Cy7, CD31-PE, CD49d-
FITC, beta7-APC (BD Biosciences), and incubated for 15 minutes at room
temperature in the dark. Red cells were lysed, and the samplewas then washed
with PBS. CD41CD311a4/b7low naive and CD41CD312a4/b7high memory
T cells were collected in PBS and stored as a pellet at 2808C.
gDNA isolation from gut microdissected and sorted
CD41 T cells
About 50,000 mm2 of microdissected CD4 T cells and 100,000 sorted
CD41CD312a4/b7high memory and CD41CD311a4/b7low naive T cells
were lysed inproteinaseKbuffer (Qiagen,Germantown,Md). Thenucleic acids
werepurifiedwithChelex 100 (Bio-Rad,Hercules,Calif) and concentratedwith
Amicon Ultra 0.5 mL filters (Merck KGaA, Millipore, Darmstadt, Germany).
FOXP3 sequence analysis
Genomic DNA (gDNA) was isolated from peripheral blood using the
QIAamp DNA Blood Mini Kit (Qiagen). The FOXP3 coding sequence,
including the exon-intron junction and the poly-A region were amplified
from gDNA by PCR with specific primer pairs flanking the regions of interest,
using a 2700 thermal cycler (ThermoFisher Scientific, Life Technologies,Wal-
tham, Mass). Primer pair sequences were already reported in the literature.E5
Approximately 50 ng of genomic DNAwere amplified with the following
conditions: 948C 4 minutes, 35 cycles at 948C 30 seconds, 30 seconds at a
primer-specific melting temperature, and 688C for 30 seconds, with a final
extension at 688C for 5 minutes. PCR products were purified using the
ExoSAP-IT reagent (Affymetrix, USB, Santa Clara, Calif) and sequenced by
using theBigDyeTerminator Cycle SequencingKit (ThermoFisher Scientific,
Life Technologies) on an automated 3130 3 l Genetic Analyzer (Thermo
Fisher Scientific, Life Technologies). Sequencing analysiswas carried outwith
BioEdit sequence alignment software (Ibis Therapeutics, Carlsbad, Calif).
Chimerism analysis
Chimerism was evaluated by multiple fluorescent short tandem repeat
analysis using the AmpFlSTR Identifiler amplification kit (Thermo Fisher
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Scientific, Life Technologies) according to the manufacturer’s instructions.
The tetranucleotide short tandem repeats loci amplified in this reaction
included D8S1179, D21S11, D7S820, and CSF1PO (all labeled with 6-FAM
blue dye); D3S1358, TH01, D13S317, D16S539, and D2S1338 (all labeled
with VIC green dye); D19S3433, vWA, TPOX, and D18S51 (all labeled with
NED yellow dye); and D5S818 and FGA (all labeled with PET red dye). In
addition, the amelogenin locus was analyzed to differentiate the X and Y
chromosomes (labeled with PET red dye). The PCR products were analyzed
with an ABI PRISM 310 DNA Genetic Analyzer (Thermo Fisher Scientific,
Life Technologies). Fragment size and peak area data were determined by
GeneScan software (Thermo Fisher Scientific, Life Technologies). The degree
of chimerism was calculated using the method described elsewhere.E6
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FIG E1. Immunohistochemical staining for FOXP31 cells in pretransplant
small bowel mucosa and submucosa section from small bowel biopsy
(FOXP3 reactive nuclei are stained black, and the sections are counter-
stained with hematoxylin).
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FIG E2. Intracytoplasmic FOXP3 expression in peripheral blood cells before
and at indicated time points after transplant. Gates for analysis were set
on CD41CD251bright T cells. x axis/arrow, Fluorescence intensity; y axis, cell
counts.
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FIG E3. Timeline representingexperimentsandanalysisperformedduring thisstudy.HE, Hematoxylin-eosin.
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FIG E4. Absolute count of T, B, and natural killer (NK) cells (per uL blood) in peripheral blood pre- and
post-HSCT (3, 6, 9, and 12 months).
J ALLERGY CLIN IMMUNOL
VOLUME 135, NUMBER 1
LETTERS TO THE EDITOR 262.e6
FIG E5. Donor cell chimerism in peripheral blood T cells (CD31), B cells (CD191), and monocytes (CD151)
during 1 year post-transplant, shown in months (m).
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FIG E6. Histopathological findings of the resected small bowel specimens. Hematoxylin-eosin (HE) staining
showed loss of mucosal epithelium with total villous atrophy at both 3 months (A) and 4 months (B) post-
transplant and long slender villi with normal brush borders at 6 months post-transplant (C). No histologic
evidence of GvHD.
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